meplazumab   Click here for help

GtoPdb Ligand ID: 11026

Synonyms: HP6H8 | Ketantin®
Antimalarial Ligand
Compound class: Antibody
Comment: Meplazumab is a humanized IgG2 monoclonal antibody that targets CD147 (basigin). It is being developed by Jiangsu Pacific Meinuoke Bio Pharmaceutical.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.

SARS-CoV-2 and COVID-19: SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells [2]. Meplazumab can block this interaction between CD147 and SARS-CoV-2 spike protein.
1. Bian H, Zheng Z-H, Wei D, Zhang Z, Kang W-Z, Hao C-Q, Dong K, Kang W, Xia J-L, Miao J-L et al.. (2020)
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial.
medrxivorg, Preprint. DOI: 10.1101/2020.03.21.20040691
2. Wang K, Chen W, Zhou Y-S, Lian JQ, Zhang Z, Du P, Gong L, Zhang Y, Cui H-Y, Geng J-J et al.. (2020)
SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.
bioRxivorg, Preprint. DOI: 10.1101/2020.03.14.988345
3. Zhang K, Zhao Y, Zhang Z, Zhang M, Wu X, Bian H, Zhu P, Chen Z. 
Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant Plasmodium falciparum.
Acta Pharmaceutica Sinica B, In press. DOI: 10.1016/j.apsb.2020.06.011
4. Zhang MY, Zhang Y, Wu XD, Zhang K, Lin P, Bian HJ, Qin MM, Huang W, Wei D, Zhang Z et al.. (2018)
Disrupting CD147-RAP2 interaction abrogates erythrocyte invasion by Plasmodium falciparum.
Blood, 131 (10): 1111-1121. [PMID:29352039]